Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06608160
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-19
Brief Title:
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
68Ga-grazytracer PETCT Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer a Prospective Observational Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy Most patients rely on follow-up observations to monitor the disease which does not meet clinical needs 68Ga-grazytracer is a novel imaging agent targeting granzyme B By detecting the concentration of granzyme B it reflects the localization of cytotoxic T cells in the tumor region and their potential ability to kill tumor cells This study aims to leverage the simplicity non-invasiveness visualization and semi-quantitative advantages of 68Ga-grazytracer PET imaging to evaluate its effectiveness and feasibility in diagnosing pseudoprogression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None